Mark Toland is the CEO of MMI SpA. Before joining MMI, Mark served as the President and CEO of Corindus where he transformed the company into the industry leader in vascular robotics with the only approved system for coronary, peripheral and neurovascular indications. The Siemens Healthineers acquisition of Corindus for $1.1 billion was the fifth largest medical technology acquisition of 2019. Prior to Corindus, Mark served as Senior Vice President of Boston Scientific, where he built the company’s global solutions business and led all aspects of the U.S. commercial team’s cardiovascular businesses, which represented approximately $4 billion in revenue. Mark brings over 25 years of medical device experience to MMI. In addition, he serves on the Board of Directors for Cardiologs, a cardiovascular AI company, and Amplitude Vascular Systems, an Intravascular Lithotripsy company. He also serves as a partner and EIR at Biostar Capital, a healthcare focused Venture Capital firm, and as CEO of Amplitude Vascular Systems (AVS), a BioStar portfolio company. Mr. Toland holds a Bachelor of Science in Business Administration from the University of Louisville.